GlassScriptPhysician profile
Paul A Michas
NPI 1750355574
$22,847.37
in general payments reported to CMS, 2019-2025
23 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,974 · 2020: $2,981 · 2021: $3,938 · 2022: $1,859 · 2023: $3,912 · 2024: $1,961 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,290 · Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,289.82 |
| Food and Beverage | $1,805.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $12,266.39 | 2019-2024 | |
| Cgg Medical INC | $8,553.31 | 2019-2025 | |
| Organogenesis INC. | $450.90 | 2020-2023 | Puraply |
| Djo, LLC | $302.47 | 2019-2025 | Cmf |
| Boston Scientific Corporation | $229.68 | 2021-2022 | |
| Horizon Therapeutics Plc | $217.95 | 2019-2022 | |
| Pacira Therapeutics, INC. | $162.81 | 2019-2021 | |
| Bioventus LLC | $144.86 | 2022-2025 | Exogen Ultrasound Bone Healing System, Durolane, Xcell |
| Depuy Synthes Sales INC. | $76.34 | 2019-2020 | |
| Smith+Nephew, INC. | $66.39 | 2022 | |
| Zimmer Biomet Holdings, INC. | $60.63 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $60.17 | 2021-2025 | Exparel |
| Baxter Healthcare | $52.22 | 2022 | |
| Si-Bone, INC. | $34.14 | 2019-2020 | |
| Convatec INC. | $22.74 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $22.52 | 2022 | |
| Moximed, INC | $22.30 | 2024 | Misha Knee System, Small, Left |
| Amgen INC. | $20.04 | 2019 | |
| Innovation Technologies INC | $19.69 | 2024 | Irrisept |
| Vertex Pharmaceuticals Incorporated | $19.49 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.67 | 2019 | |
| Baudax Bio INC. | $14.44 | 2021 | |
| Novo Nordisk INC | $13.22 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Michas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.